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Amanda Marie Campbell 
INVESTIGATION OF THE ACTION OF PHOSPHATASE OF REGENERATING 
LIVER ON PTEN USING MURINE MODELS 
The addition and removal of phosphate groups is a key regulatory mechanism for 
many cellular processes.  The balance between phosphorylation and 
dephosphorylation is delicate and must be maintained in order for proper cell 
functions to be carried out.  Protein kinases and phosphatases are the keepers of 
this balance with kinases adding phosphate groups and phosphatases removing 
them.  As such, mutation and/or altered regulation of these proteins can be the 
driving factor in disease.  Phosphatase of Regenerating Liver (PRL) is a family 
novel of three dual specificity phosphatases (DSPs) first discovered in the 
regenerating liver tissue of rats.  PRLs have also been shown to act as 
oncogenes in cell culture and in animal models.  However, the physiological 
substrate and mechanisms of the PRLs are not yet known.   Recently, our lab 
has developed a PRL 2 knockout mouse and found several striking phenotypes 
all of which correspond to a significant increase in PTEN.  We also found that 
PRL 2 is targetable by small molecular inhibitors that can potentially be used to 
disrupt tumor growth and spermatogenesis.  Furthermore, a PTEN heterozygous 
mouse model crossed into our PRL 2 knockout line was generated to investigate 
the relevance of PRL interaction with PTEN in cancer. 
Zhong-Yin Zhang, Ph.D.,Chair 
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CHAPTER 1: Introduction 
1.1  Phosphorylation 
Phosphorylation is the addition and removal of phosphate groups to organic 
molecules in cells (9, 24, 62, 78).  This evolutionarily conserved process is used 
as a regulatory mechanism for many cellular pathways (24, 62, 78). The reaction 
itself is covalent, reversible, and carried out on a variety of substrates by kinases 
and phosphatases (9, 24, 62, 78).  Specifically, kinases add phosphate groups to 
substrates while phosphatases remove them (Figure 1.) (9, 24, 62, 78).  These 
enzymes predominately phosphorylate/dephosphorylate amino acids on proteins 
(which this thesis will focus on) although examples of enzymes that 
phosphorylate/dephosphorylate lipids and nucleic acids exist (9, 24, 62, 78).  The 
amino acids that can be modified are usually serine, threonine, and tyrosine due 
to their highly reactive hydroxyl groups (9, 24, 62, 78).                 
1.1.1 Kinases and Phosphatases 
Kinases and phosphatases act as contrasting regulatory enzymes for many 
cellular pathways including metabolism, apoptosis, transcription, cell proliferation, 
and migration (9, 24, 62, 78).  As such, kinases and phosphatases together 
constitute the largest families of genes in eukaryotic organisms (9, 24, 62, 78).  
Due to the diversity of the pathways they regulate, kinases and phosphatases 
are commonly found mutated or otherwise altered in many diseases, including 
cancer, diabetes, and neurodegenerative disorders, making them tempting 
targets for drug therapy.  For many years, kinases have been the focus of drug 
discovery research due to the thought that phosphatases were too transient and 
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promiscuous to target with drugs (9, 24, 62, 78).  However, recent studies have 
shown evidence that phosphatases do have substrate specificity and can, in fact, 
be targeted by small molecule inhibitors in a specific manner (9, 24, 62, 78).  
Drug discovery for phosphatases was greatly facilitated by studies that furthered 
our knowledge of phosphatase catalytic domains and the unique structural 
properties that allow for specific drug targeting (9, 24, 62, 78).  However, catalytic 
domains tend to be highly conserved within families (9, 24, 62, 78).  To increase 
drug specificity scientists broke new ground by designing novel drugs that target 
unique structural features near the catalytic domain and regulatory sites (9, 24, 
62, 78).                
1.1.2 Tyrosine Phosphatases 
Protein phosphatases can generally be grouped into two superfamilies: enzymes 
that dephosphorylate serine/threonine residues (Serine/threonine phosphatases) 
and enzymes that are specific to tyrosine residues (Protein Tyrosine 
Phosphatases (PTPs)) (9, 24, 62, 78).  A majority of phosphatase genes encode 
protein tyrosine phosphatases all of which contain a conserved HCX5R active 
site motif (9, 24, 62, 78).  Typical dephosphorylation by PTPs involves an 
invariant Asp residue brought down into the catalytic domain via the hinged 
WPD-loop (9, 24, 62, 78).  The Asp then forms a hydrogen bond with the tyrosine 
residue substrate allowing the conserved active site cysteine to mount a 
nucleophilic attack (9, 24, 62, 78).  PTPs can be further divided into 4 classes 
based on differences in the catalytic domain (Table 1.) (9, 24, 62, 78).  Class I 
contains the largest and most diverse groups of PTPs including receptor-like, 
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non-transmembrane, and dual specificity phosphatases (DSPs) (9, 24, 62, 78).  
DSPs are named such due to their ability to dephosphorylate both 
serine/threonine and tyrosine residues (9, 24, 62, 78).  My thesis focuses on the 
novel DSP, phosphatase of regenerating liver (PRL).      
1.2  Phosphatase of Regenerating Liver(s) 
PRL 1 was first discovered as a strongly upregulated, immediate-early gene in 
rat livers recovering from partial hepatectomy (45).  Later, its family members, 
PRL 2 and PRL 3, were identified by searching the the Murine Expressed 
Sequence Tags database using the known sequence for PRL 1(75).  The PRLs 
were found to be highly similar in both amino acid sequence and structure to 
each other with PRL 1 and PRL 2 exhibiting 87% identity while PRL 3 exhibited 
76% and 79% identity to PRL 1 and 2 respectively (5, 75).  Further structural and 
sequential analysis allowed the PRLs to be categorized within the PTP 
superfamily (Figure 2. Structural data collected by Sijiu Liu) (5, 58).  PRL family 
members also share the CX5R active site, P-loop, and WDP loop motifs typical of 
PTPs (5, 58).  Furthermore, PRLs are hypothesized to be able to 
dephosphorylate both tyrosine and serine/threonine residues due to structural 
similarities to PTEN, Cdc14, MKP, and other dual specificity phosphatases (5, 
58). One structural feature that makes the PRLs unique from all other 
phosphatases is the presence of a CAAX prenylation motif next to a polybasic 
region in the C-terminal domain (Figure 2. Structural data collected by Sijiu Liu.) 
(5, 57, 58).  Prenylation is known to facilitate localization of proteins, such as 
oncogenes Ras and Rab, to the plasma membrane (8).  PRL has indeed been 
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shown to localize to the plasma membrane and early endosome if the C-terminal 
CAAX motif is prenylated (76). The polybasic region preceding the CAAX motif is 
also thought to be required for nuclear localization in the absence of prenylation 
and for recruitment to the membrane (57, 76).  Another interesting feature of the 
PRL family is the ability to form a trimer (Figure 2. Structural data collected by 
Sijiu Liu.) (23, 57, 58).  This trait was discovered under crystallization conditions 
by Sun et al. and Jeong et al (23,57).  It was later shown by Sun et al. that PRLs 
trimerize in vivo and that trimerization is required for proper cell migration (57).   
In human tissue, PRL 1 and 2 mRNA was found to be expressed virtually 
ubiquitously throughout all organ systems, with PRL 1 expression levels being 
slightly more restricted and weaker than PRL 2 (14).  PRL 3 however, has a 
much more restricted expression pattern, primarily in the heart, skeletal muscle, 
vasculature, and brain (38).       
1.3  Phosphatase of Regenerating Livers as Oncogenes 
1.3.1 PRL 3 
PRL-3 was first discovered as a potential oncogene in a study by Vogelstein et al 
(55).   Samples of metastatic liver lesions from colorectal cancer (CRC) patients 
were collected and applied serial analysis of gene expression (SAGE) technology 
to create a gene expression profile to compare to non-metastatic libraries (55). 
144 genes were found to be misregulated in the metastatic lesions, and of those 
144 genes, PRL 3 was the most consistently up-regulated (55).  Interestingly, the 
expression level of PRL 3 in colorectal cancer primary tumors was much lower 
than in corresponding hepatic metastatic lesions, suggesting that PRL 3 may 
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play an important role in metastasis as opposed to carcinogenesis (55).  
Subsequent studies showed that, while PRL 3 was more consistently elevated in 
liver and lung metastasis, many other types of CRC metastasis exhibited high 
PRL 3 expression as well including brain, ovary, and lymph node lesions (25).  
Furthermore, it was shown that high levels of PRL-3 expression in the CRC 
primary tumor could predict the presence of distant metastasis (25). A Kaplan-
Meier analysis for metastasis-free survival also revealed that patients with high 
levels of PRL 3 expression in resected CRC primary tumors were at a greater 
risk for liver/lung metastasis than those with low PRL 3 expression (25).  This 
suggests that PRL 3 may be useful for determining patient prognosis, allowing 
doctors to prescribe aggressive CRC cancer treatment with greater accuracy 
(25). 
The original studies linking PRL-3 expression to CRC patient prognosis 
resulted in the discovery of similar findings in other types of cancer including 
breast (20, 21, 52, 66), gastric (6, 10, 30, 43, 44, 47, ), ovarian (50, 53), liver (71, 
79), oral (22), cervical (36), esophageal (34), lung cancer (1, 73), multiple 
myeloma (7, 16), acute myeloid leukemia (AML) (72, 80), and nasopharyngeal 
cancer (81).  As with CRC, PRL-3 overexpression is overwhelmingly correlated 
with poor prognosis and progression to metastasis in all of the aforementioned 
cancer types (Table 2). 
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1.3.2 PRL 1 and 2 
Many studies have been conducted showing the significance of PRL 3 in cancer 
and later a similar correlation was discovered with PRL 1 and 2 (Table 2).  Some 
of the earliest evidence of PRL 1 and 2 involvement in human cancer came from 
a study focusing on the generation of PRL 1 and 3 monoclonal antibodies to be 
used to diagnose cancer metastasis (28).  Li et al. tested PRL 1 and PRL 3 
specific antibodies on a human multiple cancer tissue array (28).  The PRL 1 
antibody reacted positively to 10 different cancer tissues including renal 
carcinoma and ovary lymphoma (28).  Additionally, Wang et al. provided 
evidence that PRL 2 can serve as an oncogene in prostate cancer (67).  In this 
study, PRL 2 was shown to be overexpressed in prostate cancer cell lines 
LNCaP, PC3, and DU145 (67).  Concordantly, PRL 2 transcription was found to 
be elevated in three samples of advanced prostate cancer in comparison to the 
corresponding normal prostate tissue (67).  Recently, a study by Dumaual et al. 
showed that both PRL 1 and 2 mRNAs are highly to moderately expressed in all 
but six tumor tissue samples examined in the study (15). 
1.4  Cell function 
The first insights to the molecular basis for PRL involvement in metastasis and 
cancer was from a study published in 2003 (74).  Using a Chinese Hamster 
Ovary (CHO) cell line stably expressing Myc-tagged-PRL 1,  3, or β-Gal (control), 
the authors ascertained the effect of PRL 1 and 3 overexpression on cell mobility 
and cell invasiveness (74). PRL expressing cells were found to be significantly 
more mobile and invasive than the controls (74). Additionally, cells expressing a 
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catalytically inactive, mutant PRL showed significantly less activity and 
movement than WT controls, confirming that PRL 3 played an important role in 
cellular migration and that its ability to induce migration is dependent on its 
phosphatase activity (74).  Several papers were published later with similar 
results in both mouse melanoma and HEK293 cells lines (3, 5, 11, 18, 51, 56, 69, 
74).  Studies by Sun et al. also revealed that PRL trimerization and the presence 
of the C-terminal polybasic regions and prenylation motif were also required to 
incite the oncogenic phenotype (57).  Additionally, a study by Wang et al. 
revealed that PRL 2 can also affect cell migration and invasion (68).     
Along with cell migration, invasion, adhesion, and proliferation PRLs have 
been shown to affect cell apoptosis and angiogenesis.  Three papers revealed a 
novel connection between PRLs and p53 (Figure 3, Table 3).  Basak et al. show 
that PRL 3 is upregulated in a p53-dependent manner after submitting control 
and Doxorubicin (DNA damaging agent)-treated murine embryonic fibroblast 
(MEF) cells to a microarray analysis (4).  A scan of the PRL 3 locus revealed two 
p53 binding sites, one of which p53 was shown to bind to directly via chromatin 
immunoprecipitation (4).  Additionally, two papers by Min et al. showed that p53 
could also be regulated by PRL 1 and 3 in cancer cells (41, 42).  Upregulation of 
PRL 1 and 3 can both inhibit p53 and p53-mediated apoptosis individually with 
the opposite being true when PRL 1 or 3 is knocked down (41, 42).  Western blot 
analysis of PRL 1 or 3 overexpressing cells reveals that apoptosis inhibition can 
be caused by PRL-mediated activation of MDM2 via PI3K activation and PIRH2 
(p53 ubiquitinase) transcription via EGR1 activation (Figure 3, Table 3) (41,42). 
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Many early PRL studies have noted PRL-3 to be strongly expressed in 
tumor vasculature and hypothesized that it may play a role in induction of 
angiogenesis (18, 19, 79).  A recent paper by Xu et al. explored the molecular 
mechanism of PRL-driven HUVEC tube formation in detail (70).  In this study, 
vascular endothelial growth factor (VEGF) is shown to induce the transcription of 
PRL-3 in HUVEC cells via MEF2C transcription factor (Figure 3, Table 3) (70).  
Furthermore, VEGF could not induce PRL-3 expression when MEF2C was 
knocked down by siRNA and PRL 3 knockdown in HUVEC resulted in 
compromised tube formation (70).  
1.5 Cell Signaling                 
Since its discovery as an oncogene in colorectal cancer, PRL has been 
exhaustively researched in cell culture.  However, no putative substrate has been 
discovered.  Despite this, studies have shown evidence that PRLs can alter 
several major cell signaling pathways, including PTEN and Src (Figure 3, Table 
3) (31,32,65).  One of the first mechanistic pathways to be associated with PRL 
is Src and its downstream targets.  A study by Liang et al. showed that when 
PRL 3 was overexpressed in HEK293 cells Src kinase activity was increased by 
180% in comparison to control and PRL 3 C104S mutant cells (31).  Downstream 
targets of Src, ERK1/2, STAT3, and p130Cas, also experienced increased 
phosphorylation (Figure 3, Table 3) (31).  Purified PRL-3 was not able to 
phosphorylate Src directly; however, Csk protein (negative regulator of Src) 
expression was shown to be significantly reduced in cells overexpressing PRL 3 
(Figure 3, Table 3) (31).  When Csk was reconstituted to normal levels, via 
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tetracycline expression in cells overexpressing PRL 3, Src phosphorylation and 
the oncogenic phenotype of PRL 3 was negated (31).  A follow up study on the 
activity of PRL 3 on Csk revealed that PRL 3 could inhibit Csk translation due to 
increased phosphorylation of Ser-51 of eIF2α (Figure 3, Table 3) (32).  
Subsequent studies indicated that PRL 1 can also activate the Src pathway (32, 
35).  However, unlike PRL 3, PRL 1 activation increased Tyrosine 416 as 
opposed to Tyr527 and increased FAK activation along with pre-established 
p130Cas, ERK1/2, and STAT3 (Figure 3, Table 3) (35).  Additionally, active 
forms of matrix metalloproteinases 2 and 9 (MMP 2 and 9) were expressed at 
higher levels than in control cells (Figure 3, Table 3) (35).  MMP2 and 9 are 
regulated by ERK1/2 and degrade collagen of the basement membrane (35).  
The two proteins are often found overexpressed in cancer, providing another 
pathway through which PRL can induce cell migration (35).     
 PRLs have also been shown to regulate Rho and Rac activity in SW480 
cells (Figure 3, Table 3) (17).  Rho A, C, and Rac are known facilitators of the 
actin polymerization associated with cell mobility (17).  In cells that have been 
transfected with PRL 1 and  3 overexpression vectors, RhoA, and RhoC 
expression levels increased by 4- to 7-fold while Rac was greatly reduced (17).  
Further testing showed that in order to promote cell invasion and mobility in a 
Rho-dependent manor requires the presence of Rho effector ROCK and PRL 
phosphatase activity (17).   
 PRL is also known for interacting with integrins, E-cadherin, γ-catenin, 
vinculin and other adhesive proteins to modulate cell migration and invasiveness 
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(Figure 3, Table 3) (33, 46, 48, 61, 65).  When upregulated, PRL can enhance 
integrin β activity directly and suppress integrin α via inhibition of c-fos (Figure 3, 
Table 3) (33).  Epithelial markers such as E-cadherin are downregulated when 
PRL is over expressed while mesenchymal markers fibronectin and Snail are up-
regulated (Figure 3, Table 3) (65).  The adhesive proteins are upstream of 
PI3K/Akt, which has been shown to be up-regulated in DLD-1 cells 
overexpressing PRL 3 (65).  The mechanism for this action may be the result of 
PTEN downregulation (Figure 3, Table 3) (65).  PTEN is the negative regulator of 
the PI3K pathway and is down-regulated in DLD-1 cells over-expressing PRL 3 
(65).  PRL-mediated Src and PTEN/Akt activation can also be explained by 
upstream activity with receptor tyrosine kinases (RTKs) (Figure 3, Table 3).  
Indeed, PRL-3 has been shown to up-regulate PDGFR, Eph, and integrin 
receptor array in a proteomic analysis of HEK293 cells overexpressing PRL 3 
(Figure 3, Table 3) (64). Another study also revealed evidence of PRL 3 induced 
activation of EGFR in A431 epidermoid carcinoma cells (2).  PRL 3 
overexpression induced a state of EGFR addiction in both cell lines and in patient 
tumor sample, causing hypersensitivity to EGFR inhibition (2).  It was concluded 
that PRL 3 regulates EGFR by transcriptionally down-regulating PTP1B, causing 
EGFR hyperphosphorylation and activation (2).  
Several independent studies also show that PRL effects some additional 
pathways including upregulation of KCNN4 potassium channels (27), activity 
toward phosphoinositides (40), induction of micro RNAs (miR) 21, 17, 19a (77), 
and interaction with miR-495 and miR551a (Figure 3, Table 3) (29).  One study 
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proposes a novel role of PRL-3 downstream of an internal tandem duplication 
mutant of fms-like tyrosine kinase 3 (FLT3-ITD) present in approximately 25% of 
AML patients (Figure 3, Table 3) (80).  While studying the mechanism behind 
FLT3-ITD-positive AML drug resistance Zhou et al. treated AML cell lines with 
both FLT3 inhibitor ABT-869 and a histone deacetylase inhibitor suberoylanilide 
hydroxamic acid (SAHA) and were successful in reducing AML colony formation 
and inducing apoptosis in tumor cells (80).  Further studies revealed that PRL 3 
was strongly downregulated in cells that received combined ABT-869 and SAHA 
treatment and showed evidence that PRL 3 may be responsible for FTL3 drug 
resistance through activation of the Stat-pathway, interaction with histone 
deacetylase 4, and upregulation of Mcl-1 (80). 
1.6  Research Goals 
Much of the pre-existing data on PRL was gathered from cell culture, thus there 
is a dearth of knowledge regarding the physiological relevance of PRL in vivo.  
The Zhang lab was amongst the first in the field to develop traditional PRL knock 
out (KO) mice.  My project focuses mainly on the study of the physiological 
impact of PRL using the PRL KO and other murine models.  Specifically, I 
investigate the impact of PRL 2 deletion on spermatogenesis and the potential 
for PRL as a target for male contraception using a small molecule inhibitor 
developed by our lab.  I also created a PRL 2 KO mouse line crossed to a 
conditional, PTEN heterozygous knockout line to determine the relevancy of PRL 
2 interaction with PTEN in tumorigenesis. 
 
12 
 
 
 
 
 
Figure 1.  The basic mechanism of protein phosphorylation 
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Class I Class II Class III Class IV 
Receptor PTPs LMW-PTP CDC25 EYA 
PTPRG    
PTPRZ    
PTPRD    
PTPRF    
PTPRS    
PTPRB    
DEP1    
SAP1    
PTPRO    
PTPRK    
PTPRM    
PTPRT    
PTPRA    
Non-Receptor PTPs    
PTPN13    
PTPN14    
PTPN21    
PTPN3    
PTPN5    
PTPN7    
PTP-PEST    
PTPN18    
PTPN6    
PTPN11    
PTPN1    
PTPN2    
DSPs    
PTENs    
SSHs    
MTMRs    
CDC14s    
PRLs    
MKPs    
Atypical DSPs    
 
Table 1.  Tyrosine phosphatase classification (24). 
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Table 2.  A summary of studies of PRL in cancer. 
Cancer Type
Primary Tumors 
with High PRL 
Expression
Metastasis with 
High Levels of PRL 
Expression?
High expression 
of PRL in Primary 
tumor predictive 
of Metastasis?
Clinical Features 
Affected by PRL 
Overexpression
Clinical Features 
NOT Affected by 
PRL 
Overexpression
Reference
Colorectal Yes Yes:  Especially in 
lung and liver
Yes: Distant 
Metastasis
Chance of Distant 
metastasis   
Significant reduction 
in Disease-free 
survival (DFS)
Lymph-node 
metastasis. 
Tumor Size.  
Tumor stage.
(25, 49, 55, 60)
Breast Yes: 116 out of 
135 (85.9%) 
samples of DCIS 
and 190 out of 
246 (77.2%) 
samples of 
invasive 
carcinoma
Yes Yes:  Distant 
Metastasis
Decrease in disease-
free survival, overall 
trend   Significant 
decrease in DFS in 
node-positive 
samples (but not 
node-negative)
Lymph-node 
metastasis. 
Tumor stage.
(52)
Breast
Yes: 133 out of 
382 (34.8%) 
samples
Yes No Data Significant decrease 
in DFS in node-
negative patients  
(but not node-
positive)
Tumor stage.  
Age
(66)
Breast Yes Yes Yes: Increased 
lymph-node and 
distant metastasis
Significantly 
correlated with 
lymph-node 
metastasis  
Decrease in DFS 
Tumor stage. (20)
Gastric Yes Yes Yes: Increased 
lymph-node and 
distant metastasis
Significant decrease 
in DFS and distant 
metastasis 
Tumor stage.  
Tumor size.
(6, 10, 30, 37, 43, 
44, 47)
Ovarian Yes Yes Yes: Increased 
metastasis
Significant decrease 
in DFS and distant 
metastasis
No data. (50, 53)
Liver Yes Yes Yes: Increased 
metastasis
Significant decrease 
in DFS and distant 
metastasis
---
(71, 79)
Oral Yes Yes Yes: Increased 
metastasis
Significant decrease 
in DFS and distant 
metastasis 
No data (22)
Cervical Yes Yes Yes: Increased 
metastasis
Significant decrease 
in DFS and distant 
metastasis 
No data (36)
Esophageal Yes Yes Yes: Increased 
metastasis
Significant decrease 
in DFS and distant 
metastasis 
No data (34)
Lung Yes Yes Yes: Increased 
metastasis
Significant decrease 
in DFS and distant 
metastasis
---
(1, 73)
Multiple 
Myeloma
Yes No Data No Data Significant decrease 
in DFS
No data (7, 16)
Acute 
Myeloid 
Leukemia
Yes No Data No Data Significant decrease 
in DFS and possible 
driver for drug-
resistance
No data (72, 80)
Nasophary 
ngeal
Yes Yes Yes: Increased 
metastasis
Significant decrease 
in DFS and distant 
metastasis
No data (81)
Prostate Yes No Data No Data No Data No data (67)
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Table 3.  Summary of potential PRL binding partners 
 
Binding Partner  Effect of PRL 
Overexpression 
Reference 
p53 Inhibition  (4,41,42) 
Src Activation (31,32,25) 
ERK1/2 Activation (31,32,25) 
STAT3 Activation (31,32,25) 
p130Cas Activation (31,32,25) 
Csk Inhibition (31,32) 
MMPs Activation (35) 
FAK Activation (PRL-1) (35) 
Rho A and C Activation (17) 
Rac Inhibition (17) 
Integrin α Inhibition (33, 48) 
Integrin β Enhance Src 
interaction 
(61) 
c-fos Inhibition  (33) 
Actin 
Cytoskeleton 
Uncoupling from 
adhesive proteins 
(46) 
E-Cadherin Inhibition (65) 
γ-catenin Inhibition (65) 
Vinculin Inhibition (65) 
Fibronectin Protein level Up-
regulation 
(65) 
Snail Protein Level Up-
regulation 
(65) 
PTEN Inhibition (12,13,65) 
Akt Activation (12,13,65) 
PDGFR Activation (64) 
Eph Activation (64) 
EGFR Activation (2) 
PTP1B Inhibition (2) 
KCNN4 Activation (27) 
Phosphoinositides Dephosphorylation (40) 
miR 21,17,19a Induction (77) 
miR 495, 551a Induction (29) 
STAT5 Activation (80) 
Histone 
Deacetylase 4 
Activation  (80) 
Mcl-1 Induction (80) 
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CHAPTER 2: Materials and Methods 
 
2.1  Mouse Model Lines 
The PRL 2 Genetic Knockout line used in this study was originally generated by 
Yuanshu Dong and Yunpeng Bai from the lab of Zhong-Yin Zhang.  The mice 
were developed using a commercially available gene trap embryonic stem cell 
(AQ0673; 129P2/OlaHsd) acquired from the Sanger Institute that contained a 
pGT01 cassette inserted within the first intron of the Prl2 gene (13).  The 
embryonic stem cell (ES) was then injected into C57BL/6 blastocysts by the 
Indiana University School of Medicine Transgenic Core Facility (13).  Wildtype, 
heterozygous, and knockout animals were used (Figure 4. Figure made by 
Yuanshu Dong). 
The conditional PTEN knockout line used was originally developed by 
Antonio D. Cristofano from the Pandolfi Lab and was generously donated to the 
Zhang Lab by Yan Liu of Indiana University’s School of Medicine (Figure 5. 
Figure made by Lloyd C. Trotman) (63)). 
The pure C57BL/6 mouse line and EIIA-Cre mouse line were both 
purchased from Jackson Lab. 
2.2  Genotyping 
All DNA used for genotyping our experimental mice were gathered from toe 
tissue clipped from 7-10 day old pups.  The tissue was then lysed in Tissue Lysis 
Buffer (25mL 2M NaCl, 10mL 1M Tris pH 8.0, 10 mL 0.5M EDTA, 1% SDS) with 
freshly added proteinase K overnight at 65°C.  The DNA was then separated 
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from solution with isopropanol and re-suspended in TE buffer (10mM Tris, pH 
8.0, 1 mM EDTA) for long-term storage.  All PCR was performed using the Go 
Taq DNA Polymerase kit from Promega.    
2.2.1  PRL 2  
To determine the genotype of PRL 2 mice the primer set (donated by Qi Zeng): 
Forward 5'GGCTGTAACAGGGTGGAAGA3' and Reverse 
5'GCCACCAACATCTGGGTACT3' was used along with the following PCR cycle 
program: 
Initial Denaturation: 94°C for 5 mins 
Denaturation: 94°C for 30 seconds 
Annealing: 55°C for 30 seconds 
Elongation: 72°C for 1 min 
35 cycles 
Final Elongation: 72°C for 1 min  
2.2.2  PTEN flox 
To detect the PTEN floxed allele the primer set (donated by Yan Liu): Forward  
5'TGTTTTTGACCAATTAAAGTAGGCTGTG-3' and Reverse 
5'AAAAGTTCCCCTGCTGATGATTTGT3' were used. 
To detect the PTEN deleted allele the primer set Forward 
5'CCCCCAAGTCAATTGTTAGGTCTGT3'  and Reverse 
5'AAAAGTTCCCCTGCTGATGATTTGT3' were used along with the following 
PCR cycle program: 
Initial Denaturation: 95°C for 3 mins 
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Denaturation: 95°C for 30 seconds 
Annealing: 57°C for 30 seconds 
Elongation: 72°C for 1 min 
35 cycles 
Final Elongation: 72°C for 10 min 
2.3  Western Blot 
Tissues were snap frozen in liquid nitrogen on the day of the mouse dissection 
and later lysed using buffer containing 25mL 1M Tris HCl (pH 7.4), 18.75mL 4M 
NaCl, 2.5mL Triton X, 50mL Glycerol, and H2O to 500mL along with freshly 
prepared protease and phosphatase inhibitors (cOmplete Tablets EDTA-free, 
EASYpack, and PhosSTOP EASYpack from Roche).  3x SDS-PAGE buffer was 
added to the lysate to a final concentration of 1x and equal amounts of lysate 
were resolved on SDS-PAGE gels.  The proteins were then transferred to 
nitrocellulose membranes and treated with primary and secondary antibodies 
according to the official product recommendations.  The proteins on the 
membrane were visualized on CL-XPosure film (Thermo Scientific) after 
treatment with SuperSignal West Femto Chemiluminescent and/or Maximum 
Sensitivity Substrate from Thermo Scientific.  Visible bands were quantified using 
ImageJ software.    
2.4  Histology 
Tissues were fixed in 4% paraformaldehyde for 48 hours at room temperature, 
embedded in paraffin, serially sectioned (7 micron thickness), and stained with 
hematoxylin and eosin according to standard procedures. 
21 
 
2.5 Sperm Count 
The epididymis from treated and untreated mice were collected and minced in 
separate petri dishes containing 10mL of 1x PBS.  The plates were incubated for 
1 hour at room temperature to allow sperm to migrate from the minced 
epididymis out into the PBS.  The sperm was then collected in conical tubes, 
vortexed, and counted using a hemocytometer.    
2.6 Treatment with Compound 43 and DMSO 
Compound 43 injections were prepared by first dissolving Compound 43 in 
DMSO then adding 1x PBS to 10mL.  This leaves a final concentration of 38.4 
mM Compound 43 in 37% DMSO.  37% DMSO in 1x PBS was prepared as the 
control treatment.  The mice then received intraperitoneal injections of 
Compound 43 or DMSO in PBS at a concentration of 50mg/mL once a day for 
three weeks.   
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Figure 4.  Generation of PRL 2 Knockout mice.  A) Representation of 
the PRL 2 locus and the mutant allele containing the pGT01 gene trap 
cassette. Numbered exons (ATG) of  PRL2 are shown (13). The boxes 
labeled Lac Z and neo indicate β-galactosidase and neomycin resistance 
genes respectively (13). pA and SA indicate the polyadenylation signal 
and  splice acceptor respectively (13).  The black arrows show  primer 
sites for  PCR genotyping (13).  B) PCR amplification bands for PRL 2 
genotyping (13). C)  Quantitative RT-PCR analysis of PRL2 mRNA 
expression in tissues from PRL2 KO, PRL2 HET, and PRL2WT mice in 
skeletal muscle, kidney and lung tissue.  n= 3 mice per group(13). D) 
Western blot analyses of PRL2 protein levels in skeletal muscle from 
PRL2 KO, PRL2 HET, and PRL2 WT mice (13). E) Quantitative RT-PCR 
analysis of PRL1, PRL2, and PRL3 mRNA expression as a percentage 
of WT(13).  Figure made by Yuanshu Dong. 
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Figure 5.  Generation of conditional PTEN knockout mice.  A) The wild type 
and LoxP mutant loci are represented here (63).  Endonuclease restriction sites 
are labeled along with the neomycin resistance gene, thymidine kinase gene, 
and sections targeting homologous recombination (blue dotted line) (63).  LoxP 
sites are indicated by light blue triangles flanking exons 4, 5, and the neomycin 
gene (63).  The thick, black arrows indicate primer sites used for PCR 
genotyping (63).  B) Bottom right: Genotyping bands for PTEN WT allele, floxed 
allele, and deleted allele (63).  Figure created by Lloyd C. Trotman, Pandolfi 
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CHAPTER 3: PRL 2 Deletion Causes Progressive Degradation of 
Spermatogenesis and Loss of Germ Cells in Murine Testis 
 
3.1  Introduction 
3.1.1 Generation of PRL 2 Genetic Knockout Mouse Line 
PRL 2 KO mice were generated by Dong et al. using a commercially available 
gene trap embryonic stem cell (Sanger Institute) that contained a pGT01 
cassette inserted within the first intron of the Prl2 gene (13).  The embryonic 
stem cell (ES) was then injected into C57BL/6 blastocysts by the Indiana 
University School of Medicine Transgenic Core Facility (13).  The resulting 
chimeric mice were crossed to pure C57BL/6 wildtype (WT) mice (Jackson Lab) 
and the first PRL -/+ animals were successfully obtained (13).  The heterozygous 
animals produced all three genotypes (PRL 2 -/-, -/+, and +/+) when interbred 
(15).  Deletion of PRL 2 was confirmed using PCR and Western Blot (Figure 4. 
Figure made by Yuanshu Dong) (13). 
3.1.2  Deletion of PRL 2 Causes Reduced Testis Weight and Infertility in Male 
Knockout Mice 
After knockout PRL 2 mice were obtained, several abnormal phenotypes were 
observed.  The most noticeable result of PRL 2 deletion in mice was growth 
retardation in KO mice in comparison to wildtype siblings (13).  Newly born 
knockout mice were, on average, 20% smaller than WT mice and remained 
smaller into adulthood and beyond (13).  Most organ systems in the KO mice 
were proportionately small and revealed no abnormalities under histological 
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scrutiny (13).  Two exceptions to this finding were the testis and placenta of the 
KO animal (12, 13).  Both organs were significantly smaller than the testis and 
placenta of WT control mice (12,13).  My work focuses on the testis phenotype. 
Since the KO mice were naturally smaller that their WT siblings, Dong et 
al. normalized the organ to body weight and found that the testis were still 
significantly smaller than WT (12).  In order to investigate the impact of the 
reduced testis size on fertility cohorts of PRL 2 KO and WT males at three and 
six months old were mated to two, age-matched C57BL/6 WT females every day 
for 6 days (12).  Vaginal plugs were observed and the plug efficiency was found 
to be similar between PRL 2 KO and WT males, indicating no reduction in sex 
drive in the KO males (12).  However, sperm counts for KO males indicated 
significantly less active spermatozoa than at both 3 and 6 months old (12).  
Furthermore, the number of females plugged by PRL KO males that became 
pregnant was 20% as opposed to 70% for PRL 2 WT (12).  This reduction in 
fertility was observed in PRL 2 KO males at 3 months and 6 months with 6 month 
old males being significantly less fertile that 3 month old mice (12).          
Since testosterone can drastically affect fertility, serum testosterone levels 
were measured for PRL 2 KO and WT males.  No significant difference was 
discovered(12).      
3.2  PRL 2 Knockout Males Suffer Progressive Degradation of Spermatogenesis 
and Loss of Germ Cells 
To investigate the cause of the progressive infertility in PRL 2 KO male mice, I 
gathered samples of 3 month old and 6 month old PRL 2 KO and WT testis and 
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preserved them in paraffin wax (Figure 6).  I then analyzed histological testis 
cross-sections for abnormalities.  In the testicular cross-sections of 3 month old 
PRL 2 KO, I found that many of the seminiferous tubules had stared to shed 
some of the germ cells into the lumen (Figure 6B).  This was evidenced by a 
smaller seminiferous tubule diameter and the presence of large, multi-nuclear 
germ cells in the lumen (Figure 6B).  Otherwise, most cross-sections had well-
structured seminiferous tubules with mature spermatids being ejected into the 
lumen.  However, when I examined 6 month old PRL 2 KO testis, I found that the 
shedding of the germ cells had worsened significantly (Figure 6B).  Large 
sections of seminiferous tubules appeared to have completely shed the germ cell 
lining into the lumen.  Furthermore, 86% of seminiferous tubules were at end 
stage spermatogenesis (mature spermatids in the lumen) in 6 month old PRL 2 
WT testis while only 29% of tubules were at end stage spermatogenesis in PRL 2 
KO mice.  Additionally, shed germ cell were found in the epididymis of PRL 2 KO 
mice at both 3 and 6 months old along with a visibly reduced amount of stored, 
mature sperm (Figure 7B).         
3.3 Discussion   
The study was continued by Dong et al. to determine the mechanism responsible 
for the progressive infertility and germ cell loss in the testis of PRL 2 KO male 
mice. The seminiferous tubules of PRL 2 KO mice were found to be hypocellular 
which is consistent with the shorter diameter of seminiferous tubules as well as 
the smaller testis size (12). Seminiferous tubules cells consist of three cell types, 
Sertoli cells, germ cells, and peritubular myoid cells (12).  Sertoli cells provide 
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nourishment and structural support for the germ cells (12). Thus, the loss of 
Sertoli cells could result in loss of germ cells (12). However, visualizing the 
Sertoli cells using and anti-vimentin marker showed that the average number of 
Sertoli cells in each seminiferous tubules was similar between the two genotypes 
(12).  Thus, it can be concluded that the progressive infertility of the PRL 2 KO 
males is due to the loss of germ cells due to PRL 2 deletion (12).  Our mutant KO 
allele of PRL 2 contains lacZ under the expression control of the native PRL 2 
promoter, and can be used to monitor PRL 2 expression patterns via X-gal 
staining (12).  In PRL 2 KO mice, the germ cells stained positive for lacZ 
indicating that PRL 2 is expressed in the testis and particularly in spermatogonia 
and spermatocytes (12).    
To determine whether the testicular hypocellularity was due to decreased 
proliferation, increased apoptosis, or a combination of both, immunohistological 
staining for PCNA (Proliferating Cell Nuclear Antigen, a proliferation marker) and 
cleaved PARP (Poly ADP-Ribose Polymerase, an apoptosis marker) was 
performed on testis sections of PRL2 KO and WT mice at 2 weeks of age (12). 
There was no significant decrease in the amount of PCNA present between 
genotypes, but Cleaved-PARP was greatly increased in KO testis in comparison 
to WT (12).  The shedding of the germ cells from the lining of the seminiferous 
tubules of PRL 2 KO mice was ultimately shown to be due to an increase in 
apoptosis (12). 
Additionally, PTEN was found to be upregulated in KO testis along with 
the concordant attenuation of the c-kit-PI3K-Akt pathway (12).  PI3K-Akt 
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signaling is critically important for cell survival, thus it’s attenuation in PRL 2 KO 
germ cells could explain the dramatic increase in apoptosis in comparison to wild 
type (12).   
This study was the first to reveal that PRL 2 plays an important role in 
spermatogenesis. PRL2 KO males display testis hypotrophy, impaired 
reproductivity, and decreased sperm production all as a result of compromised 
spermatogenesis (12). As in the PRL 2 KO placenta, hypocellularity of the 
knockout testis can be explained by an increase in PTEN and attenuation of the 
PI3K-Akt pathway (12, 13).  However, unlike the KO placenta, this effect is 
reflected in an increase in apoptosis as opposed to a decrease in cell 
proliferation as seen in the placenta (12,13).   
The ability of PRL 2 to affect PTEN in vivo presents exciting possibilities 
as a potential target for cancer therapy.  PTEN is the negative regulator of the 
PI3K-Akt pathway and one of the most commonly mutated tumor suppressor 
genes found in cancer.  Further studies targeting PRL 2 with small molecule 
inhibitors can establish whether or not PRL 2 can serve as a novel target for 
cancer therapy as well as determine the value as a potential drug for male 
contraception. 
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Figure 6.  Seminiferous tubules of PRL 2 KO male mice display 
progressive degradation of spermatogenesis and shedding of germ cells 
into the lumen.  A)  This PRL 2 wildtype seminiferous tubule is healthy 
and well-structured with spermatogonia lining the outside, spermatocytes 
in the middle, and mature spermatids about to be released into the lumen 
tail first.  B)  At 3 months old, PRL 2 KO seminiferous tubules are still well 
structured but have a significantly reduced thickness in comparison to 
WT and have large, apoptotic cells being shed into the lumen (black 
arrow).  At six months large sections of PRL 2 KO seminiferous tubules 
have completely shed their germ cell lining into the lumen.       
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Figure 7.  Germ Cells are shed into the epididymis of PRL 2 KO mice.  A) At 
three months of age, PRL 2 WT epididymis is healthy and full of mature 
sperm (stained purple).  B) The epididymis of PRL 2 KO male have apoptotic 
germ cell debris shed in the lumen (black arrows) and show significantly less 
healthy sperm stored in comparison to WT. 
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CHAPTER 4: EVALUATION OF PRL AS A POTENTIAL TARGET FOR MALE 
CONTRACEPTION USING PRL INHIBITOR, COMPOUND 43 
 
4.1 Treatment of Wildtype C57BL/6 mice with Compound 43 
Since the ability of PRL to disrupt spermatogenesis was shown by Dong et al. the 
potential for use as a male contraceptive became a tempting cause for research.  
Recently, our lab has developed a novel, small molecular inhibitor of PRLs 
(Figure 8. Structure made by Yunpeng Bai.).  The drug targets the trimerization 
domain of PRL and prevents trimerization which was previously shown to be 
important for PRL-driven cell migration and invasiveness through PTEN-Akt and 
ERK signaling (57).  Since, the drug inhibits PTEN signaling through PRL and it 
is known that the ability of PRL 2 to disrupt spermatogenesis is correlated to 
PTEN, I decided to conduct a mouse study exploring the effects of Compound 43 
on male WT C57BL/6 mice.  I hypothesized that treating the WT mice with 
compound 43 would result in a PRL 2 KO phenotype of reduced 
spermatogenesis and infertility.  I treated one cohort of 4 male mice with 50 
mg/kg of Compound 43 dissolved in dimethyl sulfoxide (DMSO), and a control 
cohort of 5 male mice with an equal concentration of pure DMSO once a day for 
three weeks.  The cohorts were subjected to a breeding efficiency experiment 
and at the end of the three week period were sacrificed and dissected for 
analysis. 
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4.1.1 Treatment of Mice Cohorts for Three Weeks Did not Induce Growth 
Retardation 
At the end of the three week treatment period, mice were weighed to determine if 
inhibiting PRL with Compound 43 would reproduce the growth retardation 
phenotype present in the PRL 2 genetic knockout.  The weights were not 
significantly different between the treatment groups (Figure 9C).  
4.1.2 Three Week Treatment with Compound 43 Was Not Sufficient to Induce 
Infertility  
PRL 2 KO males have difficulty producing pups.  To assess the ability of PRL 2 
inhibitor to induce infertility, each male mouse was mated to two virgin, C57BL/6 
WT females during the last two and a half days of the three week treatment with 
Compound 43 and DMSO.  Treatment was continued during breeding.  
Treatment did not affect plugging efficiency.  Over the two and a half days 8 out 
of 8 of the females paired to Compound 43 treated males were plugged and 8/10 
females paired to the DMSO controls were found to be plugged.  Of the females 
plugged, however, 5 out of 8 females paired to Compound 43 treated males 
became pregnant while only 4 of the 10 females paired to control mice gave 
birth.  Additionally, sperm collected from the minced epididymis of the mice 
showed no difference between treatment groups when counted with a 
hemocytometer (Figure 9B).  Thus, we can conclude that treatment with 
Compound 43 for three weeks will not reproduce the infertility phenotype of the 
genetic PRL 2 KO mice.  
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4.1.3 Three Week Compound 43 Treatment Did Not Reproduce PRL 2 Knockout 
Phenotypes in the Testis 
In the PRL 2 KO male, the testis were significantly smaller than WT and 
hypocellular (14).  Shedding of germ cells into the lumen of the seminiferous 
tubules was also observed(14). To test if treatment with compound 43 could 
reproduce this phenotype the testis of treated and untreated mice were collected 
and weighed.  The size of the testis where PRL 2 was inhibited were not smaller 
than untreated testis (Figure 9A,D).  In fact, the testis treated by Compound 43 
were slightly larger than DMSO controls (Figure 9A,D).  This may be due to 
inflammation caused by off-site effects of the drug.  Furthermore, no germ cells 
were observed in the lumen of the seminiferous tubules or epididymis of either 
treatment group when the testis were analyzed histologically (Figure 10 and 
Figure 11).       
4.1.4 Weak PTEN Pathway Activation Detected after Three Week Treatment 
To determine if Compound 43 could upregulate PTEN and downregulate PI3K-
Akt signaling in the testis, I used whole testis lysate for Western Blot analysis.  
PTEN was found to be weakly upregulated in Compound 43 treated testis, as 
expected based on data from the PRL 2 KO mouse (Figure 12A,B).  C-kit was 
also downregulated and apoptosis slightly increased (based on Cleaved PARP 
levels) in Compound 43 testis (Figure 9A).  However, p-Akt was not 
downregulated in PRL 2 inhibited mice (Figure 9A).  I would expect p-Akt to be 
decreased in Compound 43 mice in comparison to control mice, however, Akt 
phosphorylation seems to be upregulated in PRL 2 inhibited mice (14).  
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4.2 Discussion     
This study shows that treatment with Compound 43 for three weeks is insufficient 
to reproduce the infertility phenotype present in the PRL 2 KO model although 
weak activation of PTEN was detected.  The expected results were that 
treatment with Compound 43 would induce infertility, testis hypocellularity, 
shedding of c-kit positive germ cells into the lumen, and activation of PTEN as 
was observed in the genetic knockout of PRL 2.  In fact, since the drug targets all 
three members of the PRL family equally, I expected greater degradation of 
spermatogenesis as is seen in PRL 2 KO: PRL 1 HT mice.  However, the 
shedding of germ cells is a prolonged process in our genetic models, even with 
the combined partial deletion of PRL 1 (hypothesized to compensate for deleted 
PRL 2 in the testis).  Thus, in future studies I would propose to treat the mice for 
12 to 16 weeks.  Furthermore, I would improve the statistical data by using larger 
cohorts of male mice in each treatment group.  I would like at least 8-10 animals 
per group.  Also, the discrepancy in the birth rates between PRL inhibited and 
DMSO treated groups may be due to the fact that the females used for breeding 
were not age matched and only two females per male was used.  In future 
studies, I would like to have at least six females per male to assess pregnancy 
efficiency, and would like females to be no younger than 3 months old and no 
older than 5 months old.  This will ensure accurate statistics and reduce the 
skewing of pregnancy rates due to the females being too old or too young.   
 Before this study, Compound 43 had not been assessed for toxicity.  This 
is important for assessing the usability of Compound 43 as a male contraceptive.  
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One way to check for off-site effects is to measure testosterone, luteinizing 
hormone, and follicle stimulating hormone levels in the serum using an ELIZA 
assay (39).  If the protein levels of these hormones differ from the control group, 
there is an increased chance that the PRL drug can disrupt organ systems and 
pathways outside of the testis in a toxic manner(39).  The kidneys can also be 
assessed for histological evidence of kidney damage (39).  Detection of blood in 
the urine is also indicative of drug toxicity(39).  During long term treatments, the 
mice may suffer a general degradation in health and well-being.   
 Furthermore, if treatment of WT mice with Compound 43 for a longer 
period does result in infertility I would be interested in testing if the effect is 
reversible.  Reversibility is particularly important if the drug is to be used as a 
contraceptive.  In order to do this, I would treat cohorts of 8-10 male mice with 
Compound 43 or DMSO for a sufficient time to induce infertility (will be 
determined based of previous study and confirmed with a pregnancy efficiency 
test) then cease treatment in increasing and decreasing increments of time (3, 6, 
9, 12, and 16 weeks).  Then, the breeding and plugging efficiency tests will be 
repeated to determine if fertility is regained.  Testis will also be collected and 
compared to the testis of mice treated with Compound 43 or DMSO to an 
equivalent point of infertility.  If infertility caused by treatment with Compound 43 
is reversible, I would expect a complete return of fertility and no difference in the 
histology and PTEN signaling of the testis between DMSO and Compound 43 
treated groups. 
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 Before this study, Compound 43 has never been used on mice as a tool to 
study PRL.  If we find that Compound 43 does cause significant off-site effects in 
organ systems besides the testis it can still serve as a powerful tool to study the 
role of PRL in normal physiology.  Our lab has created knockout lines of all three 
PRL family members, but only PRL 2 has shown an observable phenotype.  
There is evidence that the other PRLs can partially compensate for deleted PRL 
family members due to their high sequence and structural similarity.  Thus, in 
order to truly dissect the role of PRLs in vivo a triple knockout must be 
developed.  However, this had been confounded in our mouse models due to the 
embryonic lethality of PRL 1 and 2 double knock out mice.  Compound 43, on the 
other hand, knocks out all PRL family member with equal affinity and can be 
delivered during adulthood to circumvent any lethal developmental abnormalities 
present in the genetic model.  This has the potential to bring out new phenotypes 
in organ systems that express more than one PRL family member.  I would like to 
treat WT C57BL/6 mice with Compound 43 and observe different PRL-rich organ 
systems such as the brain and nervous system, colon, bones, spleen, 
regenerating liver, and thyroid gland for new abnormalities.  This can help close 
the knowledge gap in the role of PRL in normal physiology and may reveal 
additional potential binding partners for research.  We can also check for 
increased severity in other phenotypes present in PRL 2 KO animals.  PRL 2 KO 
animals have hypocellular placentas and a more recently discovered deficiency 
in hematopoiesis (12, 13, 26).  PRL-2 null hematopoietic stem and progenitor 
cells (HSPCs) are more quiescent and show reduced activation of the Akt and 
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ERK1/2 signaling as a result of an increase in PTEN level (26). Furthermore, 
PRL-2 is found to be important for SCF-mediated HSPC proliferation and loss of 
PRL-2 decreased the ability of oncogenic KIT/D814V mutant in promoting 
hematopoietic progenitor cell proliferation (26). Thus, PRL-2 plays critical roles in 
regulating HSC self-renewal and mediating SCF/Kit signaling(26).  
 PRL was brought into the spotlight when it was discovered as an 
oncogene.  Compound 43 can potentially be used for cancer therapy.  In the 
future, we can treat mice injected with cancer cells with Compound 43 to 
determine if inhibition of PRL trimerization is sufficient to delay tumorigenesis.   
Compound 43 has great potential as a tool to study the role of PRL in cancer and 
in normal physiology in future studies. 
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Figure 8.  The chemical structure of Compound 43.  Structure 
made by Yunpeng Bai. 
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Figure 9.  Treatment of C57BL/6 WT males with Compound 43 for three 
weeks did not replicate PRL 2 KO phenotypes.  Expected results were that 
mice treated with Compound 43 would have reduced testis weight and body 
weight to testis weight ratio and have reduced sperm count.  However, results 
A. B. 
C. D. 
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Figure 10.  The seminiferous tubules of Compound 43 treated mice and 
DMSO treated mice are both healthy and have no shed germ cells in the 
lumen.  
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Figure 11.  The epididymides of Compound 43 and DMSO treated mice.  
Healthy, contain no she germ cells and are full of mature sperm. 
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CHAPTER 5: Creation of a Heterozygous PTEN Murine Cancer Model Crossed 
on PRL 2 Knockout Background 
 
5.1  Mouse Model Generation 
Using small molecular inhibitors is one way to investigate the role of PRL in 
cancer.  Genetic models can also be used in conjunction with chemical models to 
provide more physiologically relevant data.  Previous studies from our lab shows 
that PRL 2 can act as a negative regulator of PTEN in spermatogenesis (12).  
Since PTEN is one of the most commonly mutated tumor suppressors found in 
cancer, I generated a Cre-driven PTEN heterozygous knockout line crossed with 
our PRL 2 KO line to investigate whether PRL interaction with PTEN is relevant 
during tumorigenesis.  Akira Suzuki et al. created a mouse line with traditional 
knockout deletion of PTEN on exons 3-5 and demonstrated that PTEN deletion 
can increase cancer risk in a dose-dependent manor (59).  The PTEN Null mice 
were found to be embryonic lethal (59).  However, heterozygous null mice were 
viable and exhibited an increased incidence of breast, thyroid, prostate, 
intestinal, brain, and liver cancer as well as T-cell lymphoma/leukemia by the 
time they reached six months of age (59).  I hypothesize that PRL 2 deletion in a 
PTEN heterozygous murine model will delay the PTEN tumorigenesis phenotype.       
5.1.1 Generation of PTEN flox/flox : PRL -/+ Mice 
To create my PTEN/PRL 2 cross, I acquired a conditional knockout PTEN mouse 
line (C57BL/6 background) from Yan Liu (Indiana University School of Medicine, 
Department of Pediatrics) originally developed by Trotman et al.  This PTEN 
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mouse model uses LoxP/Cre method of deletion with exons 4 and 5 flanked by 
LoxP sites.  Upon introduction of Cre recombinase, PTEN will become truncated 
and inactive.   
 My first round of breeding involved two male PTEN flox/flox mice acquired 
from the Liu lab and four PRL 2 knockout female mice backcrossed onto 
C57BL/6 for seven generations arranged into two trios (Figure 13A).  The 
resulting pups were all PTEN flox/+ and PRL 2 -/+.  Next, I backcrossed the 
PTEN/PRL 2 double heterozygous offspring to their PTEN flox/flox father to 
generate PTEN flox/flox : PRL 2 -/+ mice (Figure 13A,B).      
5.1.2 Generation of Cre-induced PTEN heterozygous Knockout Mice on PRL 2 
KO background 
To create a full body PTEN heterozygous knockout mouse on a PRL 2 knockout 
background I choose to purchase two C57BL/6 females homozygous for EIIA-
Cre from Jackson Lab.  EIIA-Cre puts Cre recombinase under the control of the 
strong, viral promoter, EIIA.  I then create a single trio of two EIIA-Cre +/+ female 
mice crossed to one PTEN flox/flox : PRL 2 -/+ male (Figure 14A).  The resulting 
litter should produce pups with one PTEN floxdeleted and one wildtype PTEN allele 
as well as either PRL 2 +/+ or PRL 2 -/+ (Figure 14A).  From the first litter, I 
obtained my first PTEN floxdeleted/+ mouse as determined by PCR genotyping 
(Figure 14B).  Unfortunately, she inherited two wildtype PRL2 alleles so she will 
have to be bred back into the PRL 2 KO line.   
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5.2  Discussion 
In this project I successfully obtained my first PTEN floxdeleted/+ mouse.  Once I 
breed the female back into the PRL 2 knockout line I will obtain pups with PTEN 
floxdeleted/+ : PRL 2 +/- genotypes.  My original cross of PTEN flox/flox : PRL 2 -/+ 
with the two EIIA-Cre females will also provide me with pups of this genotype.  At 
this point I can dissect the pups to confirm ubiquitous deletion of PTEN via PCR 
and Western blot.  I will then breed PTEN floxdeleted/+ : PRL 2 +/- mice together to 
obtain PTEN floxdeleted/+ : PRL 2 -/-, PTEN floxdeleted/+ : PRL 2 +/+, PTEN +/+ : 
PRL 2 -/-, and PTEN +/+: PRL 2 +/+ pups (Figure 15).  These four genotypes will 
serve as the experimental and control cohorts for my future study on the effect of 
PRL 2 deletion on PTEN-driven tumorigenesis.  I plan to generate 8-10 mice per 
genotype  and gender, with  PTEN floxdeleted/+ : PRL 2 -/-, PTEN floxdeleted/+ : PRL 
2 +/+ as the experimental cohorts and PTEN +/+ : PRL 2 -/-, and PTEN +/+: PRL 
2 +/+ serving as controls.  I hypothesize that PTEN floxdeleted/+ : PRL 2 -/- mice 
will have a delayed tumorigenesis phenotype in comparison to PTEN floxdeleted/+ : 
PRL 2 +/+.  I do not expect my control cohorts to develop PTEN-driven cancer.  
After establishing my cohorts, I will observe my mice throughout their lifespan.  
Mice will be monitored for cancer and end point determination will be based on 
signs of sickness and distress.  The signs include: hunched posture, reduced 
food/water intake, lack of grooming, palpable tumors, and general health 
deterioration.  At the end point, tumors from the mice will be counted and 
weighed.  Tumors from the different cohorts will also be saved and examined for 
differences in tumor structure, cell death, cell proliferation, and development 
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through histology and immunohistochemistry.  If PRL works up stream of PTEN 
as a negative regulator we should see a delayed tumorigenesis phenotype.  On a 
western blot we should see PTEN levels higher than 50% and decreased Akt 
levels.  If PRL does not affect the PTEN pathway there will be no difference 
between PTEN floxdeleted/+ : PRL 2 +/+ and PTEN floxdeleted/+: PRL -/-.  
Furthermore, PTEN level reduction in PTEN may also rescue the PRL 2 KO 
fertility and growth phenotypes.   
While crossing PRL 2 with PTEN heterozygous cancer model is one way 
to interrogate PRL 2 interaction with PTEN, the model will take at least nine 
months to produce any noticeable difference in tumor load between the 
experimental and control cohorts.  PRL 2 was originally hypothesized to be an 
oncogene.  Thus, crossing PTEN flox mice to PRL 2 transgenic mice would 
quickly provide complementary confirmation to results gathered from the 
PTEN/PRL 2KO cross.  I hypothesize that PRL 2 transgenic mice would act as a 
second-hit mutation for the PTEN heterozygous mice and expedite tumorigenesis 
in the PTEN floxdeleted/+:PRL2 Transgenic mice in comparison to PTEN 
floxdeleted/+:PRL2 +/+ controls.  Cohorts will include 8-10 mice from the following 
genotypes: PTEN floxdeleted/+:PRL2 Transgenic, PTEN floxdeleted/+:PRL2 +/+, 
PTEN +/+:PRL2 Transgenic, and PTEN +/+: PRL 2 +/+. Mice with PTEN 
floxdeleted/+ will already be established as a line from the preceding study, 
simplifying the breeding strategy.  PRL 2 transgenic mice have yet to be 
developed in our lab, however, once a transgenic line has been established I will 
cross PTEN floxdeleted/+ to PRL 2 transgenic mice to produce my cohorts.  Again, 
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I will observe the mice until palpable tumors are present.  The mice will then be 
sacrificed and the tumors collected and counted.  Along with a heavier tumor 
load, I expect decreased PTEN protein levels if PRL works upstream of PTEN 
and no effect on PTEN if it works on a parallel pathway.  As in the above study, 
Akt, p-Akt, ERK, p53, Src and their downstream targets will also be examined via 
western blot.  Performing this study will allow us to evaluate PTEN as a potential 
target of PRL.     
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Figure 13.  Breeding strategy to obtain PTEN flox/flox mice on PRL 2 
background.  A)  Breeding strategy.  B) The red boxes are examples of mice that 
have the desired genotype. 
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Figure 14.  Strategy to obtain PTEN heterozygous Cre mice on PRL 2 
background.  A) Breeding strategy.  B) The red box is mouse #48.  She is 
the first PTEN heterozygous Cre mouse generated.  
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Figure 15.  Breeding strategy for four experimental cohorts. 
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